Crohn's disease, fatigue, and infliximab: Is there a role for cytokines in the pathogenesis of fatigue?

World Journal of Gastroenterology

Volumn 13, Issue 14, 2007, Pages 2089-2093

  Minderhoud, Itta M ^a   Samsom, Melvin ^a   Oldenburg, Bas ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Crohn's disease; Cytokines; Fatigue; Infliximab

Indexed keywords

AZATHIOPRINE; CYTOKINE; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; MESALAZINE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; CYTOKINE RELEASE; DEPRESSION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG INFUSION; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SINGLE BLIND PROCEDURE;

EID: 34249085886     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i14.2089     Document Type: Article

References (33)

1. Minderhoud IM, Oldenburg B, van Dam PS, van Berge Henegouwen GP. High prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiency. Am J Gastroenterol 2003; 98: 1088-1093
2. Gupta S, Aggarwal S, See D, Starr A. Cytokine production by adherent and non-adherent mononuclear cells in chronic fatigue syndrome. J Psychiatr Res 1997; 31: 149-156
3. Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation 2005; 12: 255-269
4. Buchwald D, Wener MH, Pearlman T, Kith P. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol 1997; 24: 372-376
5. Vollmer-Conna U, Lloyd A, Hickie I, Wakefield D. Chronic fatigue syndrome: an immunological perspective. Aust N Z J Psychiatry 1998; 32: 523-527
6. Maerten P, Shen C, Colpaert S, Liu Z, Bullens DA, van Assche G, Penninckx F, Geboes K, Vanham G, Rutgeerts P, Ceuppens JL. Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models. Clin Exp Immunol 2004; 135: 310-317
7. Monteleone G, Trapasso F, Parrello T, Biancone L, Stella A, Iuliano R, Luzza F, Fusco A, Pallone F. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999; 163: 143-147
8. Stallmach A, Giese T, Schmidt C, Ludwig B, Mueller-Molaian I, Meuer SC. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis 2004; 19: 308-315
9. Gasche C, Bakos S, Dejaco C, Tillinger W, Zakeri S, Reinisch W. IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease. J Clin Immunol 2000; 20: 362-370
10. Reinisch W, Gasche C, Tillinger W, Wyatt J, Lichtenberger C, Willheim M, Dejaco C, Waldhor T, Bakos S, Vogelsang H, Gangl A, Lochs H. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 1999; 94: 2156-2164
11. Furuya D, Yagihashi A, Komatsu M, Masashi N, Tsuji N, Kobayashi D, Watanabe N. Serum interleukin-18 concentrations in patients with inflammatory bowel disease. J Immunother 2002; 25 Suppl 1: S65-S67
12. D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999; 116: 1029-1034
13. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035
14. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405
15. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50: 206-211
16. Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002; 8: 237-243
17. Persoons P, Demyttenaere K, Vandenberghe J, Van Oudenhove L, Rutgeerts P. The evolution of fatigue in patients with Crohn's disease after treatment with Infliximab: A Prospective Study. Gastroenterology 2004; 126: A-476-T1354, abstract
18. Lennard Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6; discussion 16-19
19. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39: 315-325
20. Smets EM, Garssen B, Bonke B. Het meten van vermoeidheid met de multidimensionele vermoeidheidindex (MVI-20) 1995. Een handleiding (Dutch guidelines for use of MFI). Medische Psychologie, Academisch Medisch Centrum, Universiteit van Amsterdam
21. Smets EM, Garssen B, Cull A, de Haes JC. Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy. Br J Cancer 1996; 73: 241-245
22. Smets EM, Visser MR, Willems-Groot AF, Garssen B, Oldenburger F, van Tienhoven G, de Haes JC. Fatigue and radiotherapy: (A) experience in patients undergoing treatment. Br J Cancer 1998; 78: 899-906
23. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-810
24. Russel MG, Pastoor CJ, Brandon S, Rijken J, Engels LG, van der Heijde DM, Stockbrugger RW. Validation of the Dutch translation of the Inflammatory Bowel Disease Questionnaire (IBDQ): a health-related quality of life questionnaire in inflammatory bowel disease. Digestion 1997; 58: 282-288
25. Bouma J, Ranchor AV, Sanderman R, Sonderen vE. Het meten van symptomen van een depressie met de CES-D, 1995. Een handleiding (Dutch guidelines for use of CES-D). Rijksuniversiteit Groningen, Noordelijk Centrum voor Gezondheidsvraagstukken, Groningen
26. Radloff LS. The CES-D Scale: a Self-report Depression scale for research in the General population. Appl Psychol Meas 1977; 1: 385-401
27. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444
28. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995; 20: 27-32
29. de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003; 10: 133-139
30. de Jager W, Prakken BJ, Bijlsma JW, Kuis W, Rijkers GT. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods 2005; 300: 124-135
31. van Balkom BP, Schoon EJ, Stockbrugger RW, Wolters FL, van Hogezand RA, van Deventer SJ, Oldenburg B, van Dullemen HM, Russel MG. Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease. Aliment Pharmacol Ther 2002; 16: 1101-1107
32. Persoons P, Vermeire S, Demyttenaere K, Fischler B, Vandenberghe J, Van Oudenhove L, Pierik M, Hlavaty T, Van Assche G, Noman M, Rutgeerts P. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab. Aliment Pharmacol Ther 2005; 22: 101-110
33. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004; 126: 1257-1269